Abstract
In two ongoing phase I trials, PC14586, a Y220C-selective structural corrector of mutant p53, and BI 907828, an MDM2–p53 antagonist, appear safe and tolerable, showing signs of efficacy. These emerging data offer hope that a key tumor suppressor may not be as undruggable as previously thought.
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
You do not currently have access to this content.